Skip to main content
PMC home page
Frontiers in Cellular and Infection Microbiology logoLink to Frontiers in Cellular and Infection Microbiology
. 2017 Apr 28;7:153. doi: 10.3389/fcimb.2017.00153

Positive Effect of Probiotics on Constipation in Children: A Systematic Review and Meta-Analysis of Six Randomized Controlled Trials

Ruixue Huang 1, Jianan Hu 1,*
PMCID: PMC5408016  PMID: 28503492

Abstract

Context: Constipation in children is a prevalent, burdensome, and psychologically important pediatric issue, the treatment of which remains a global challenge. The use of probiotics has been reported for management of the gastrointestinal microbiota.

Objective: This study reviewed the existing literatures of 6 Randomized Control Trials (RCTs) to ascertain some baseline understanding and available information for the effects of probiotics on stool frequency and consistency in children with constipation.

Data Sources: PubMed, Springer, Elsevier Science, Cochrane Library, Scopus, Ovid (Medline, EMBASE, PsycINFO), Orbis, and Web of Science from the earliest record in each database to 15 September, 2016.

Study selection: Eligible studies were randomized controlled trials that compared the effect of probiotics interventions to any control intervention on stool frequency and consistency.

Data Extraction: Studies were identified by searching electronic databases. The meta-analysis was performed by Review Manager 5.3 software using a randomized model.

Results: Six studies were identified. The use of probiotics significantly increased the stool frequency [mean difference (MD), 0.73; 95% confidence interval (CI), 0.14–1.31; P = 0.02]. Subgroup assessment showed a significantly increased stool frequency in Asian patients (MD, 1.18; 95% CI, 0.33–2.02; P = 0.006), but no significant difference in stool consistency (MD, −0.07; 95% CI, −0.21–0.06; P = 0.27).

Limitations: Only six RCTs met the criteria and were included. Each RCT in this study was performed in a different country, and some of the included studies had a small sample size, which might have influenced the reliability and validity of the conclusions.

Conclusion: The present study shows that probiotics increase stool frequency and have beneficial effects in Asian children. However, caution is needed when interpreting these outcomes because of the existence of heterogeneity. Evidence from larger samples and more adequately powered RCTs with results obtained by standardized measurements are necessary to determine which species and dosage of probiotics and what length of treatment are most efficacious for constipation in children.

Keywords: probiotics, constipation, children, meta-analysis, randomized controlled trial

Introduction

Constipation, which is characterized by infrequent and painful evacuation, abdominal pain, and fecal incontinence, is a frustrating issue in pediatric healthcare worldwide. The estimated prevalence ranges from 0.7 to 29.6% globally, including both developed and developing countries (Rajindrajith et al., 2016). Constipation is also a familiar disease in pediatric emergency clinics and can have distressing physical effects on affected children, as well as psychological effects on both children and their families (Koppen et al., 2016a). Moreover, constipation is the primary complaint in 3–5% of children who present to pediatric physicians and represents the cause of 10–25% of transfers to special gastroenterologists (Molnar et al., 1983). Liem (Liem et al., 2009) estimated that the cost associated with childhood constipation in the United States is ~$3430/per case/per year.

According to the recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, treatment of childhood constipation usually includes parental or family education, dietary changes, toilet training, use of medications such as laxatives, and behavioral modification (Constipation Guideline Committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, 2006). Although these methods are popular, the majority of children require sustained therapy for a long period of time, and some children with constipation do not achieve satisfactory results. Statistical data show that even when treatment is sustained for 1 year, about 50% of children remain symptomatic and about 30% still struggle with this disorder (Poddar, 2016). Therefore, interest in the development and evaluation of new and more effective solutions for constipation in children is growing.

Technological developments have shown that the gut microbiota is essential for human health and that a wide variety of childhood diseases are associated with the condition of the gut microbiota (Johnson and Versalovic, 2012). Probiotics are attracting increasing attention in this regard. They are defined by the World Health Organization as live microorganisms that, when taken in certain amounts, lead to health benefits for the host (Quigley, 2015). That means probiotics are live bacteria and yeasts which has a expand spectrum including the well-known strains of Lactobacillus acidophilus, Bifidobacterium lactis, and Lactobacillus brevis that are good for your health, not only the digestive system but also other systems such as brain. In general in terms of bacteria we think it can lead to diseases, however, probiotics are typically called “good” or “helpful” bacteria because they help keep healthy. A large amount of evidence is available on the benefits of using probiotics as a strategic therapy for various gastrointestinal disorders including persistent diarrhea, community-acquired acute diarrhea, and irritable bowel syndrome (Bernaola Aponte et al., 2010; Applegate et al., 2013; Quigley, 2015; Szajewska et al., 2016). Probiotics also reportedly have potential for the treatment of constipation in children. In 2005, Benninga et al. stated that probiotics represent a new treatment option for childhood constipation (Benninga et al., 2005). Bekkali et al. (2007) conducted a pilot study to determine the effect of a mixture of probiotics including Bifidobacterium and Lactobacillus spp. on constipation and indicated that these probiotics had positive effects on the symptoms of constipation; for instance, they increased the frequency of bowel movements and decreased the number of fecal incontinence episodes per week in children (Bekkali et al., 2007). A study by Bu et al. (2007) demonstrated no significant difference in treatment efficacy between a probiotics group (Lactobacillus casei rhamnosus, Lcr35) and a control group of children with chronic constipation. Khodadad (Khodadad and Sabbaghian, 2010) used synbiotics to treat childhood constipation and found that it improved symptoms of childhood constipation without any side effects. In addition, Guerra et al. (2011) used Bifidobacterium-containing yogurt to examine its effects on childhood chronic constipation and found that the defecation frequency and severity of abdominal pain were improved. Furthermore, in 2011, a double-blind randomized controlled trial (RCT) conducted by Tabbers et al. (2011b) showed that a fermented dairy product containing B. lactis strain DN-173010 increased the stool frequency with no serious side effects. In the same year, these authors also found that Bifidobacterium breve was effective in increasing the stool frequency in children with functional constipation (Tabbers et al., 2011c). Chen (Chen et al., 2012) conducted a prospective cohort study in Taiwan in 2012 and found that mothers with higher education levels, families with higher incomes, and parents with a healthier lifestyle tended to use more probiotic supplementation for their children. These findings indicate that probiotics have a much more positive influence in this population. Moreover, in 2013, a study by Saneian et al. (2013) revealed that supplementation of mineral oil with the synbiotic Lactol (containing L. sporogenes) can improve the constipation symptoms of children without side effects. In 2014, Sadeghzadeh et al. also investigated the effectiveness of probiotics in the treatment of constipation in children and found that the stool frequency increased and the stool consistency improved with probiotics (Sadeghzadeh et al. 2014). However, according to a study by Banaszkiewica (Banaszkiewicz and Szajewska, 2005), Lactobacillus GG was not an effective adjunct to lactulose in treating constipation in children.

The human microbiome is a topic of interest for many researchers and may alter our views of health and disorders in the next several decades. To the best of our knowledge, however, the role of the human microbiome in treating constipation in children is unclear because of contradictory research findings and the lack of systematic reviews and meta-analyses of the efficacy of probiotics for constipation in children. Thus, we conducted a systematic review of RCTs to summarize the evidence of the relationship between probiotics and constipation in children and to identify heterogeneity among the RCT findings.

Methods

Inclusion criteria

The inclusion criteria were as follows: (1) The study evaluated children aged ≤ 18 years with constipation identified by relative clinical symptoms, pediatric physicians, or the Rome I, II, or III criteria. (2) The study design was an RCT. (3) Any type of culture/strain/dose/therapy regimen of probiotics was included. Synbiotics were also included because they consist of both prebiotics and probiotics (Koppen et al., 2016b). Any medication form including tablet, powder, oil suspension, or capsule was included. (4) The study included a clinical cohort and controls, and the clinical cohort's intervention was the consumption of probiotics. (5) Clinical studies used similar methods and measured stool frequency and stool consistency. The results were reported as mean ± standard deviation. When the same groups of patients were reported in multiple papers, only the most recent and complete paper was selected to avoid overlap.

Exclusion criteria

Studies that met the following criteria were excluded from the meta-analysis: (1) those with populations of patients aged >18 years with constipation; (2) pilot studies, cross-sectional studies, or other investigations without a randomized control group; (3) outcomes were presented in other ways such as figures without numerical outcomes of mean ± standard deviation; and (4) not meeting the inclusion criteria described above.

Article search strategy

Two independent researchers performed searches of the electronic databases of PubMed, Springer, Elsevier Science, Cochrane Library, Scopus, Ovid (Medline, EMBASE, PsycINFO), Orbis, and Web of Science from the earliest record in each database to 15 September, 2016. The following key words were used: “probiotics,” “prebiotics,” “synbiotics,” “Lactobacillus,” “Bifidobacterium,” “Saccharomyces,” “childhood constipation,” “constipation in children,” and “randomized controlled trials.” We also checked the references listed at the end of each publication to identify additional studies; however, only studies published in the English language were considered, and those comprising only conference abstracts were excluded due to the lack of sufficient data.

Data collection

Data collection was performed by two reviewers independently. Any eligible studies with regard to the effect of probiotics on constipation in children were collected on a tailored form and examined by the second reviewer. The form included study's author(s), publication date, population demographics, probiotic species, probiotic dosage, and treatment results (Table 1). If the study data were unclear, such as the standard deviation was lacking, we attempted to contact the corresponding author to obtain further information in detail.

Table 1.

Characteristics of included RCTs for meta-analysis.

Author, year (country) N Age Constipation definition Genus, species, and strain Dose Duration (weeks)
Banaszkiewicz and Szajewska, 2005 (Poland) 84 Probiotics: 79 months Placebo: 65 months <3 BMs per week for at least 12 weeks Lactobacillus rhamnosus GG 109colony-forming units, twice daily orally 12
Bu et al., 2007 (Taiwan) 45 Probiotics: 36.7 months Placebo: 35 months Having a stool frequency of <3 times per week for >2 months Lactobacillus casei rhamnosus, Lcr35 8 × 108c.f.u., two capsules, b.i.d 4
Khodadad et al., 2010 (Iran) 102 Synbiotics + liquid paraffin: 5.9 years, Synbiotics + Placebo: 6.2 years, Liquidparaffin + placebo: 6.9 years Rome III criteria L. casei, L. rhamnosus, S. thermophilus, B. breve, L.acidophilus, B. infantis 1 × 109CFU/1 sachet, per day 4
Sadeghzadeh et al., 2014 (Iran) 48 Probiotics: 6.1 years Control: 6.3 years Rome III criteria Lactobacillus casei, Lactobacillus rhamnosus PXN54, Streptococcus thermophiles PXN66, Bifidobacterium breve PXN25, Lactobacillus acidophilus PXN35, Bifidobacterium infantis PXN27, Lactobacillus bulgaricus 1 × 109CFU 4
Saneian, 2013, (Iran) 60 Probiotics: 5.4 years Control: 4.7 years Rome III Criteria Lactobacillus Sporogenes 15 × 107 spores,1 Tab/20 kg/day 8
Tabbers, 2011, (Netherlands, Poland) 159 Probiotics: 7 years Control: 6.5 years Rome III criteria Lactobacillus delbruec kiissp. Bulgaricus CNCM strain numbers I-1632 and I-1519, Streptococcus the rmophilus CNCM strain, Lactococcuscremoris Blactis DN-173 010 1.2 × 108CFU per pot, two pots per day 3
Open in a new tab

Statistical analysis

The meta-analysis was carried out with RevMan 5.3 software (Cochrane Collaboration 2014, Nordic Cochrane Center, Copenhagen, Denmark). Stool frequency and stool consistency were the major variables used to verify the efficacy of probiotics in the treatment of constipation in children. Because the results were continuous outcomes, the mean difference (MD) and 95% confidence interval (CI) were calculated for the summary statistics analysis, and a randomized-effects model was utilized based on the heterogeneity of the results among the studies. Subgroup analyses were also conducted for different geographic areas and different bacterial strains.

In the meta-analysis, heterogeneity across studies was assessed by the I (Koppen et al., 2016a) statistic. Statistical heterogeneity was audited using the χ2-test, and the extent of inconsistency was assessed by the I2 statistic. If I2 ≥ 50%, which indicated significant heterogeneity, we used a random-effects model for the analysis; otherwise, we used a fixed-effects model to assess the variables. Publication bias was assessed by the funnel plot. A two-tailed p < 0.05 was considered statistically significant. We performed the sensitivity analysis by excluding the studies one by one. Using the Cochrane “risk of risk” assessment tool, we assessed the risk of bias for each included RCT.

Results

Included studies

An adapted PRISMA flow diagram was used to present the process of article selection for the meta-analysis (Hutton et al., 2016). Figure 1 shows the flow diagram of studies enrolled in the meta-analysis. In the initial search, 198 articles were reviewed. At the end of the flow diagram, six studies involving 498 children met the selection criteria (Banaszkiewicz and Szajewska, 2005; Bu et al., 2007; Khodadad and Sabbaghian, 2010; Tabbers et al., 2011b; Saneian et al., 2013; Sadeghzadeh et al., 2014). The characteristics of the studies are shown in Table 1.

Figure 1.

Figure 1

Open in a new tab

PRISMA flow diagram of studies included in meta-analysis.

Quality assessment

Figure 2A shows the risk of bias across all RCTs. A plot of the distribution of the review authors' judgments regarding the risk-of-bias items across all studies is shown. Figure 2B presents a summary table of the review authors' judgments regarding each risk-of-bias item for each study. All six studies were RCTs, and risk of bias for each included RCT was low. None of the studies had a high risk of bias. Four studies divided the children into a probiotics intervention group and a control group; two studies randomly divided the children into three groups: probiotics, placebo, and other intervention. Five of the six studies were double-blind studies. All six studies reported the baseline data of each group, and the differences in these data among the groups were not statistically significant in all studies.

Figure 2.

Figure 2

Open in a new tab

(A) Bar chart comparing percentage risk of bias for each included RCT. The risk of bias was quite low. (B) Risk of bias for each included RCT, representing low risk of bias (+), high risk of bias (−), and unclear risk of bias (?).

Efficacy of probiotics stool frequency

Stool frequency was measured in all six studies. The results are shown in Figure 3. The random-effects model comparing the probiotics and control groups showed an MD of 0.73 (95% CI, 0.14–1.31; P = 0.02).

Figure 3.

Figure 3

Open in a new tab

Forest plots of RCTs in patients with constipation comparing probiotics with placebo or other intervention. Random-effects models were used to analyze the MD and 95% CI. (A) Overall outcomes of the six studies. (B) Subgroup analysis by age. (C) Subgroup analysis by geographical area.

A subgroup analysis was carried out to determine whether age affected the outcome of treatment by probiotics (Figure 3B). The ages of the children in two of the studies ranged from 3 to 5 years (MD, 1.62; 95% CI, −0.4–3.65; P = 0.12). The ages of the children in two other studies ranged from 6 to 7 years (MD, 0.28; 95% CI, −0.29–0.85; P = 0.34).

A subgroup analysis was also performed to determine whether geographical areas affected the outcome of treatment by probiotics (Figure 3C). Four studies were from Asia (MD, 1.18; 95% CI, 0.33–2.02; P = 0.006) and two studies were from Europe (MD, 0.08; 95% CI, −0.79–0.95; P = 0.86).

The stability of the results was tested by sensitivity analysis. We sequentially removed studies that did not reach statistical significance in all of the above analyses, suggesting that the results of our meta-analysis were not significantly unstable.

Stool consistency

Stool consistency was measured in three studies; the remaining three studies did not report the outcomes of stool consistency. As shown in Figure 4, the meta-analysis using a random-effects model comparing the probiotics and control groups showed an MD of −0.07 (95% CI, −0.21–0.06; P = 0.27).

Figure 4.

Figure 4

Open in a new tab

Forest plot of outcome of meta-analysis of RCTs regarding stool consistency in children with constipation.

Publication bias

A funnel plot was used to assess publication bias qualitatively. The funnel plot shown in Figure 5 is partially symmetrical, indicating no obvious evidence of asymmetry and therefore no evidence of publication bias.

Figure 5.

Figure 5

Open in a new tab

Funnel plot of publication bias analysis.

Discussion

Various studies have investigated the potential mechanisms of action by which probiotics might play a role in the treatment of constipation in children. One proposed mechanism is that probiotics beneficially change the gastrointestinal microbiota (Grehan et al., 2010). Another is that some probiotics have an antinociceptive role in which they inhibit contraction of the colonic epithelial cell cytoskeleton, which opens the tight junctions, and induce direct or indirect effects of nitric oxide in the gastrointestinal tract (Ait-Belgnaoui et al., 2006). A third proposed mechanism is that some probiotics increase the amounts of lactate and short-chain fatty acids as well as decrease the luminal pH, thus enhancing gut peristalsis (Waller et al., 2011). We performed the present meta-analysis based on the hypothesis that probiotics significantly increase stool frequency and modify stool consistency. In our previous study, we reported that probiotics had a significant effect on decreasing the depression scale score (Huang et al., 2016). In the present study, we continued to assess the effect of probiotics on other disorders such as constipation, which is common among children. The outcomes of this study demonstrate that probiotics result in a significantly increased stool frequency (Figure 3); however, there was significant heterogeneity (I2 = 80%, P = 0.02). We conducted subgroup assessments and found different effects of probiotics on stool frequency in children depending on geographical area; Asian children had a significantly higher stool frequency with probiotic treatment.

Stool frequency is a critical variable with which to assess the treatment of constipation (Tabbers et al., 2011a). The present study showed heterogeneity in the outcome of stool frequency, which positively increased by probiotic supplementation; this was particularly pronounced in Asian children. A meta-analysis on the effects of probiotics on constipation in adults published in 2014 showed outcomes similar to those of the present study (Dimidi et al., 2014). Our assessment in children and other findings in adults show that probiotics have a significant role in changing stool frequency in both children and adults. It was reported that probiotics, especially some most studied strains such as Lactobacilli and Bifidobacteria are able to produce short chain fatty acids reducing the level of intraluminal pH and promoting colonic peristalsis, which is beneficial for changing stool frequency. We carried out a subgroup assessment of age; however, the findings showed no significant difference between the 3- to 5-year-old group and the 6- to 7-year-old group. The reason for this finding may have involved the number of patients enrolled. Larger study samples have the potential to improve the statistical outcomes.

According to the Rome III criteria, stool consistency is another important index with which to evaluate constipation (Koppen et al., 2016c). Khodadad et al. (Khodadad and Sabbaghian, 2010) studied the effects of L. casei, L. rhamnosus, Streptococcus thermophilus, B. breve, and other microorganisms on stool consistency and found no statistically significant difference. In addition, Tabbers et al. (2011b) used fermented milk containing B. lactis DN-173010 to treat constipation in children, and the outcomes showed that stool consistency was not significantly different between the probiotic group and the control group. We also found that probiotics had no significant effect on improving stool consistency in children. Our findings are similar to those of former reports.

This meta-analysis contributes clinically important information on the treatment of constipation in children. When pediatric physicians treat constipation in children, probiotics represent an alternative strategy that has been shown to be efficacious, especially in terms of increasing stool frequency, which is an important measurement in constipation. On the other hand, parents often treat their children with over-the-counter medications or laxatives, which might not relieve the symptoms (Borowitz and Ritterband, 2001). Probiotics are an alternative approach for parents when their children have this problem.

We made many efforts to minimize publication bias in this meta-analysis; however, despite comprehensive and complete document retrieval and performance of the analysis by two separate researchers, this study has some limitations. First, heterogeneity of some findings was significant, which means that there was variation among the studies. This could have been caused by differences in the types and doses of probiotics among the studies, as well as differences in other factors such as diet, body condition, other medications, and sample size. Second, each RCT in this study was performed in a different country; thus, people with different genetic constitutions or microbial exposure may have had different responses to identical probiotics. Third, some of the included studies had a small sample size, which might have influenced the reliability and validity of the conclusions.

Conclusion

This meta-analysis provides some baseline understanding and available information that probiotics have the potential to increase the stool frequency; however, the findings must be interpreted with caution because of heterogeneity. Regardless, the outcomes are a source of optimism with respect to the management of constipation in children. Further evidence from larger samples and more adequately powered RCTs that use standardized measurements are necessary to assess which species and dosage of probiotics and what length of treatment are most efficacious for constipation in children.

Author contributions

JH: conceived and designed the study, performed eligibility screening, and did data extraction. After initial manuscript was completed, he critically revised the manuscript and polished the English language. He approved the final manuscript as submitted. RH: conceived and designed the study, performed eligibility screening and data extraction; as well as analyzed the data and performed the statistical analysis. She wrote the initial manuscript. He approved the final manuscript as submitted. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (81372966).

Glossary

Abbreviations

RCTs

randomized controlled trials

MD

mean difference.

References

  1. Ait-Belgnaoui A., Han W., Lamine F., Eutamene H., Fioramonti J., Bueno L., et al. (2006). Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 55, 1090–1094. 10.1136/gut.2005.084194 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Applegate J. A., Fischer Walker C. L., Ambikapathi R., Black R. E. (2013). Systematic review of probiotics for the treatment of community-acquired acute diarrhea in children. BMC Public Health 13(Suppl. 3):S16. 10.1186/1471-2458-13-S3-S16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Banaszkiewicz A., Szajewska H. (2005). Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J. Pediatr. 146, 364–369. 10.1016/j.jpeds.2004.10.022 [DOI] [PubMed] [Google Scholar]
  4. Bekkali N. L., Bongers M. E., Van den Berg M. M., Liem O., Benninga M. A. (2007). The role of a probiotics mixture in the treatment of childhood constipation: a pilot study. Nutr. J. 6:17. 10.1186/1475-2891-6-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Benninga M. A., Candy D. C., Taminiau J. A. (2005). New treatment options in childhood constipation? J. Pediatr. Gastroenterol. Nutr. 41(Suppl. 1), S56–S57. 10.1097/01.scs.0000180307.02052.56 [DOI] [PubMed] [Google Scholar]
  6. Bernaola Aponte G., Bada Mancilla C. A., Carreazo Pariasca N. Y., Rojas Galarza R. A. (2010). Probiotics for treating persistent diarrhoea in children. Cochrane Database Syst. Rev. CD007401. 10.1002/14651858.CD007401.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Borowitz S. M., Ritterband L. (2001). Using the internet to teach parents and children about constipation and encopresis. Med. Inform. Internet Med. 26, 283–295. 10.1080/14639230110086295 [DOI] [PubMed] [Google Scholar]
  8. Bu L. N., Chang M. H., Ni Y. H., Chen H. L., Cheng C. C. (2007). Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation. Pediatr. Int. 49, 485–490. 10.1111/j.1442-200X.2007.02397.x [DOI] [PubMed] [Google Scholar]
  9. Chen Y. C., Chien Y. W., Chang P. J., Hsieh W. S., Chen P. C. (2012). Probiotic supplement use among young children in Taiwan: a prospective cohort study. PLoS ONE 7:e43885. 10.1371/journal.pone.0043885 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Constipation Guideline Committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition . (2006). Evaluation and treatment of constipation in infants and children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 43, e1–13. 10.1097/01.mpg.0000233159.97667.c3 [DOI] [PubMed] [Google Scholar]
  11. Dimidi E., Christodoulides S., Fragkos K. C., Scott S. M., Whelan K. (2014). The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 100, 1075–1084. 10.3945/ajcn.114.089151 [DOI] [PubMed] [Google Scholar]
  12. Grehan M. J., Borody T. J., Leis S. M., Campbell J., Mitchell H., Wettstein A. (2010). Durable alteration of the colonic microbiota by the administration of donor fecal flora. J. Clin. Gastroenterol. 44, 551–561. 10.1097/MCG.0b013e3181e5d06b [DOI] [PubMed] [Google Scholar]
  13. Guerra P. V., Lima L. N., Souza T. C., Mazochi V., Penna F. J., Silva A. M., et al. (2011). Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J. Gastroenterol. 17, 3916–3921. 10.3748/wjg.v17.i34.3916 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Huang R., Wang K., Hu J. (2016). Effect of prbiotics on depression: a systematic review and meta-analysis of randomized controlled trials. Nutrients 8:E483. 10.3390/nu8080483 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hutton B., Catalá-López F., Moher D. (2016). [The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA]. Med. Clin. 147, 262–266. 10.1016/j.medcli.2016.02.025 [DOI] [PubMed] [Google Scholar]
  16. Johnson C. L., Versalovic J. (2012). The human microbiome and its potential importance to pediatrics. Pediatrics 129, 950–960. 10.1542/peds.2011-2736 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Khodadad A., Sabbaghian M. (2010). Role of synbiotics in the treatment of childhood constipation: a double-blind randomized placebo controlled trial. Iran. J. Pediatr. 20, 387–392. [PMC free article] [PubMed] [Google Scholar]
  18. Koppen I. J., Benninga M. A., Tabbers M. M. (2016b). Is there a role for Pre-, Pro- and synbiotics in the treatment of functional constipation in children? A systematic review. J. Pediatr. Gastroenterol. Nutr. 63(Suppl. 1), S27–S35. 10.1097/MPG.0000000000001220 [DOI] [PubMed] [Google Scholar]
  19. Koppen I. J., Di Lorenzo C., Saps M., Dinning P. G., Yacob D., Levitt M. A., et al. (2016a). Childhood constipation: finally something is moving! Expert Rev. Gastroenterol. Hepatol. 10, 141–155. 10.1586/17474124.2016.1098533 [DOI] [PubMed] [Google Scholar]
  20. Koppen I. J., Velasco-Benitez C. A., Benninga M. A., Di Lorenzo C., Saps M. (2016c). Using the bristol stool scale and parental report of stool consistency as part of the Rome III criteria for functional constipation in infants and toddlers. J. Pediatr. 177, 44–48. 10.1016/j.jpeds.2016.06.055 [DOI] [PubMed] [Google Scholar]
  21. Liem O., Harman J., Benninga M., Kelleher K., Mousa H., Di Lorenzo C. (2009). Health utilization and cost impact of childhood constipation in the United States. J. Pediatr. 154, 258–262. 10.1016/j.jpeds.2008.07.060 [DOI] [PubMed] [Google Scholar]
  22. Molnar D., Taitz L. S., Urwin O. M., Wales J. K. (1983). Anorectal manometry results in defecation disorders. Arch. Dis. Child. 58, 257–261. 10.1136/adc.58.4.257 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Poddar U. (2016). Approach to constipation in children. Indian Pediatr. 53, 319–327. 10.1007/s13312-016-0845-9 [DOI] [PubMed] [Google Scholar]
  24. Quigley E. M. (2015). Probiotics in irritable bowel syndrome: the science and the evidence. J. Clin. Gastroenterol. 49(Suppl. 1), S60–S64. 10.1097/mcg.0000000000000348 [DOI] [PubMed] [Google Scholar]
  25. Rajindrajith S., Devanarayana N. M., Crispus Perera B. J., Benninga M. A. (2016). Childhood constipation as an emerging public health problem. World J. Gastroenterol. 22, 6864–6875. 10.3748/wjg.v22.i30.6864 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Sadeghzadeh M., Rabieefar A., Khoshnevisasl P., Mousavinasab N., Eftekhari K. (2014). The effect of probiotics on childhood constipation: a randomized controlled double blind clinical trial. Int. J. Pediatr. 2014:937212. 10.1155/2014/937212 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Saneian H., Tavakkol K., Adhamian P., Gholamrezaei A. (2013). Comparison of Lactobacillus sporogenes plus mineral oil and mineral oil alone in the treatment of childhood functional constipation. J. Res. Med. Sci. 18, 85–88. [PMC free article] [PubMed] [Google Scholar]
  28. Szajewska H., Canani R. B., Guarino A., Hojsak I., Indrio F., Kolacek S., et al. (2016). Probiotics for the prevention of antibiotic-associated diarrhea in children. J. Pediatr. Gastroenterol. Nutr. 62, 495–506. 10.1097/MPG.0000000000001081 [DOI] [PubMed] [Google Scholar]
  29. Tabbers M. M., Boluyt N., Berger M. Y., Benninga M. A. (2011a). Nonpharmacologic treatments for childhood constipation: systematic review. Pediatrics 128, 753–761. 10.1542/peds.2011-0179 [DOI] [PubMed] [Google Scholar]
  30. Tabbers M. M., Chmielewska A., Roseboom M. G., Crastes N., Perrin C., Reitsma J. B., et al. (2011b). Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics 127, e1392–e1399. 10.1542/peds.2010-2590 [DOI] [PubMed] [Google Scholar]
  31. Tabbers M. M., de Milliano I., Roseboom M. G., Benninga M. A. (2011c). Is Bifidobacterium breve effective in the treatment of childhood constipation? Results from a pilot study. Nutr. J. 10:19. 10.1186/1475-2891-10-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Waller P. A., Gopal P. K., Leyer G. J., Ouwehand A. C., Reifer C., Stewart M. E., et al. (2011). Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand. J. Gastroenterol. 46, 1057–1064. 10.3109/00365521.2011.584895 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Cellular and Infection Microbiology are provided here courtesy of Frontiers Media SA

RESOURCES